FDA Determines Regulatory Review Period for SEVENFACT Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for SEVENFACT, a human biological product patent extension application submitted to the U.S. Patent and Trademark Office (USPTO). This determination is a result of the FDA's requirement to publish a notice as per law, following the USPTO's application for patent extension.